Shots: The approval follows the trials which involves assessing of HLX13 vs originator ipilimumab to evaluate its pharmacology, pharmacokinetics and toxicokinetics profiles, immunogenicity, and toxicity The study resulted in biosimilarity data in terms of in vivo and in vitro pharmacology, PK, toxicokinetics, immunogenicity and toxicity characteristics HLX13 is a recombinant anti-CTLA-4 fully human mAb injection […]Read More
